Kate Young
Kate develops and oversees strategic investments to support drug pricing reform.
Kate has worked on drug pricing issues from a variety of different vantage points. Before joining Arnold Ventures, Kate was a principal analyst within the Budget Analysis Division of the Congressional Budget Office, where she handled the Medicaid prescription drug portfolio, in addition to producing cost estimates for opioid use disorder treatment policies. Before that, she was an analyst at the Kaiser Family Foundation where she worked on the Program on Medicaid and the Uninsured, focusing on the prescription drug benefit, as well as providing data analysis expertise. Early in her career, she worked at Greylock McKinnon Associates, an economic consulting firm, where she provided analysis and other support to economists acting as subject matter experts in pharmaceutical litigation.
She holds an M.A. in economics from Boston University and received her B.A. in economics from Wellesley College.
